Insight Molecular Diagnostics (IMDX) Enterprise Value (2020 - 2025)
Insight Molecular Diagnostics (IMDX) has disclosed Enterprise Value for 6 consecutive years, with -$12.3 million as the latest value for Q4 2025.
- Quarterly Enterprise Value fell 42.57% to -$12.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$12.3 million through Dec 2025, down 42.57% year-over-year, with the annual reading at -$12.3 million for FY2025, 42.57% down from the prior year.
- Enterprise Value hit -$12.3 million in Q4 2025 for Insight Molecular Diagnostics, up from -$19.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$866000.0 in Q4 2022 to a low of -$59.8 million in Q1 2021.
- Historically, Enterprise Value has averaged -$21.4 million across 5 years, with a median of -$18.7 million in 2023.
- Biggest five-year swings in Enterprise Value: skyrocketed 97.44% in 2022 and later plummeted 989.15% in 2023.
- Year by year, Enterprise Value stood at -$33.9 million in 2021, then surged by 97.44% to -$866000.0 in 2022, then tumbled by 989.15% to -$9.4 million in 2023, then rose by 8.44% to -$8.6 million in 2024, then crashed by 42.57% to -$12.3 million in 2025.
- Business Quant data shows Enterprise Value for IMDX at -$12.3 million in Q4 2025, -$19.4 million in Q3 2025, and -$24.3 million in Q2 2025.